Viviant FDA Approval Status

FDA Approved: No
Brand name: Viviant
Generic name: bazedoxifene
Company: Pfizer Inc.
Treatment for: Prevention of Osteoporosis

Viviant (bazedoxifene) is a selective estrogen receptor modulator (SERM) in development for the prevention of postmenopausal osteoporosis.

Development timeline for Viviant

Date	Article
May 27, 2008	Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
Dec 26, 2007	Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis - Dec 26, 2007
Dec 17, 2007	Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
Apr 24, 2007	Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis - May 1, 2007
Jun 26, 2006	Wyeth Submits Two NDAs for Women’s Health Therapies

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.